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Acentralcomponentoftype2diabetesandthemetabolic
syndromeisinsulinresistance.Insulinexertsamultifaceted
and highly integrated series of actions via its intracellular
signaling systems. Generation of mice carrying null muta-
tions of the genes encoding proteins in the insulin signaling
pathway provides a unique approach to determining the
role of individual proteins in the molecular mechanism of
insulinactionandthepathogenesisofinsulinresistanceand
diabetes. The role of the four major insulin receptor sub-
strates (IRS1-4) in insulin and IGF-1 signaling have been
examined by creating mice with targeted gene knockouts.
Each produces a unique phenotype, indicating the comple-
mentaryroleofthesesignalingcomponents.Combinedhet-
erozygous defects often produce synergistic or epistatic ef-
fects, although the ﬁnal severity of the phenotype depends
on the genetic background of the mice. Conditional knock-
outs of the insulin receptor have also been created using the
Cre-lox system. These tissue speciﬁc knockouts have pro-
vide unique insights into the control of glucose homeostasis
and the pathogenesis of type 2 diabetes, and have led to de-
velopmentofnewhypothesesaboutthenatureoftheinsulin
action and development of diabetes.
Keywords Brain; Insulin Action; Insulin Receptor; Insulin Resis-
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Over 17 million people in the United States have diabetes
mellitus, and about 90% of these have the type 2 form of the
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disease. In addition, between 17 and 40 million people have
insulin resistance, impaired glucose tolerance or the cluster of
abnormalities referred to variably as the metabolic syndrome,
the dysmetabolic syndrome, syndrome X or the insulin resis-
tance syndrome. In all of these disorders, a central component
of the pathophysiology is insulin resistance. In type 2 diabetes
there is insulin resistance at the level of the muscle and fat in
terms of glucose uptake and insulin resistance at the liver in
terms of the ability of the hormone to suppress hepatic glucose
uptake (Figure 1). Under normal circumstances, this insulin
resistance would be compensated for by increased insulin se-
creation,butintype2diabetesthereisaseconddefectinwhich
the β-cell speciﬁcally loses its ability to sense glucose. This
results in insufﬁcient insulin secretion for the level of insulin
resistance, i.e. relative insulin deﬁciency, and a deterioration of
glucose tolerance. Insulin resistance is also closely linked to
other common health problems, including obesity, polycystic
ovarian disease, hyperlipidemia, hypertension and atheroscle-
rosis. Thus, understanding the complex molecular mechanisms
of insulin action and its alterations in type 2 diabetes and other
insulin resistant states is of critical importance to deﬁning the
optimal approach to this group of diseases.
THE MOLECULAR MECHANISMS
OF INSULIN ACTION
Insulin exerts a multifaceted and highly integrated series
of actions via its intracellular signaling systems which are
schematically represented in Figure 2 [1]. The insulin recep-
tor is a member of the family of receptor, tyrosine kinases.
Insulin binds to the α-subunit of the receptor, activating the
kinase which is intrinsic to the β-subunit. This results in
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FIGURE 1
Control of glucose homeostasis and its alterations in type 2 diabetes.
FIGURE 2
Schematic overview of the molecular mechanism of insulin action.KNOCKOUT MICE, HOMEOSTASIS, AND DIABETES 171
autophosphorylation of the receptor itself and futher activation
of the receptor toward intracellular substrates. Thus far, ten
intracellular substrates of the insulin receptor have been iden-
tiﬁed. The best characterized of these are the insulin receptor
substrate proteins (IRS), IRS-1, -2, -3 and -4 [2–6]. Following
tyrosine phosphorylation, each of these intracellular substrates
associates with one or more molecules through speciﬁc recog-
nitionsitestermsSH2domainstogenerateadownstreamsignal
(Figure2).ThetwomostimportantSH2domainmoleculeswith
respect to insulin action are the enzyme phosphatidylinositol
(PI) 3-kinase and the adaptor molecule Grb2 [7, 8]. PI 3-kinase
appears to be the critical link to all of the metabolic actions of
insulin [9], while Grb2 links insulin action to thr Ras-MAP ki-
nase pathway which plays a role in insulin’s ability to stimulate
cell growth and differentiation [10]. Understanding how this
pathway operates and where the defects might be in diabetes
and other insulin resistant states is complicated, not only by
the multiple IRSs, but also by the fact that each of the proteins
involved in insulin action occurs in multiple isoforms. For ex-
ample, for enzyme PI 3-kinase, there are eight known isoforms
oftheregulatorysubunitandthreeisoformsofthecatalyticsub-
unit.Sinceatleastﬁveoftheinsulinreceptorsubstratescanlink
FIGURE 3
Gene targeting by homologous recominbination. Homologous recombination between the normal endogenous gene and the
targeting vector results in a recombined inactive gene in which exon 2 (containing the start codon) has been substituted by a
neomycin cassette (neo). ES cells that survive neomycin selection are injected into blastocysts. Chimeric mice carrying the
inactivated gene are being breed to create homozygous knockout mice.
to PI 3-kinase, even in these two steps in the insulin signaling
pathway there are 120 potential combinations of signaling pro-
teins that could generate the PI 3-kinase based signal.
CREATION OF KNOCKOUT MICE
Generation of mice carrying null mutations of the genes
encoding proteins in the insulin signaling pathway provides a
uniqueapproachtodeterminingtheroleofindividualproteinsin
themolecularmechanismofinsulinactionandthepathogenesis
of insulin resistance and diabetes. Over the past decade, the
functionofhundreds,ifnotthousands,ofgenes,includingmany
forproteinsinvolvedininsulinaction,hasbeenanalyzedinvivo
by gene targeting approaches [11].
The ﬁrst step to creating global gene knockout is production
of a targeting vector containing a modiﬁed copy of the gene of
interestthatisfunctionallyinactive.Anexampleisillustratedin
Figure 3. In this case, a clone containing the endogenous gene
with the 5  ﬂanking region, the coding exons and part of the 3 
untranslated region is used to produce a targeting vector, in this
example, by deletion of exon 2, which removes the start codon.
A neomycin-resistance gene, including a stop codon, is then172 C. R. KAHN
inserted in place of the deleted exon, and the modiﬁed gene is
transferred,bymeansofhomologousrecombination,toreplace
the normal endogenous genes in embryonic stem (ES) cells.
The ES cell clones that survive the neomycin selection can be
assessed by Southern blot analysis to conﬁrm that homologous
recombination has occurred. This occurs in anywhere between
1 in 2 and 1 in 2,000 cells. The properly targeted cells are then
injected into mouse blastocysts, which in turn are implanted
into pseudopregnant foster mothers to complete development.
The chimeric pups that result can then transmit their modiﬁed
gene to the progeny. The transmission of the modiﬁed gene
can be conﬁrmed by PCR and the heterozygous carrier mice
can be bred to homogeneity. The absence of the protein can be
conﬁrmed by Western blotting of appropriate tissues.
Insulin Receptor Substrate Knockout Models
Insulin and IGF-1 initiate their actions by stimulating the
phosphorylation of a family of proteins referred to as insulin
receptor substrates. The role of the four major insulin recep-
tor substrates (IRS-1 to IRS-4) in insulin and IGF-1 signal-
ing have been examined by creating mice with targeted gene
knockouts. IRS-1 knockout (KO) mice are IGF-1 resistant and
are growth retarded both prenatally and postnatally. They ex-
hibit birth weights between 40–60% of wildtype mice, and this
persiststhroughoutadultlife[12,13].Bycontrast,IRS-2knock-
out mice have only a 10% reduction in birth weight and IRS-3
or IRS-4 knockout mice are of normal size (Table 1) [14–16].
Disruption of Irs1 also causes insulin resistance, mainly in
skeletal muscle, and abnormal glucose tolerance; however, this
doesnotleadtodiabetessincethesemicecandevelopβ-cellhy-
TABLE 1
Phenotypes of IR and IRS knockout mice
Insulin receptor Normal intrauterine growth
Severe insulin resistance
Die in 3–7 days in diabetic ketoacidosis
IRS-1 Growth retardation
Insulin resistance (muscle, fat)
β-cell hyperplasia
IRS-2 Insulin resistance (Liver)
Defect in β-cell proliferation
Diabetes
IRS-3 Normal birth weight
Normal glucose homeostasis
IRS-4 Normal growth
Very mild defect in glucose homeostasis
IRS-1/IRS-2 Embryonic and fetal lethal
IRS-1IRS-3 Lipoatrophic diabetes
Marked insulin resistance
IRS-1/IRS-4 Same as IRS-1
perplasia. The IRS-1 deﬁciency also leads to other components
of the insulin resistance syndrome, such as hypertension and
hypertryglyceridemia [17]. Isolated islets from the knockout
mice manifest a secretory defect and reduced insulin synthesis,
demonstratingaroleforIRS-1inisletfunction[18].Incontrast,
IRS-2 deﬁcient mice develop overt diabetes in early life due to
severeinsulinresistanceinliverandalackofcompensatoryhy-
perplasia from the pancreatic β-cells [14]. On the other hand,
IRS-3 and IRS-4 knockout mice show normal or only minimal
defects in glucose homeostasis (Table 1) [15, 16]. This illus-
trates the unique complementary roles of the IRS-proteins in
the insulin/IGF-1 signaling cascades, and the power of mouse
genetics to dissect these differences.
Mice with a Global Knockout of the Insulin
Receptor
A complete lack of insulin receptors in humans due to mu-
tations of the insulin receptor gene results in severe insulin re-
sistance and severe intrauterine growth-retardation, but usually
only mild to moderate diabetes [19, 20]. Mice with homozy-
gous knockout of the insulin receptor are born at term at the
expected mendelian frequency but with only a slight growth
retardation (∼10%) and without any apparent metabolic ab-
normalities [21, 22]. After birth, however, metabolic control
rapidly deteriorates: glucose levels increase upon feeding, and
insulinlevelsriseupto1,000-foldabovenormal,withnoappar-
ent effect on glucose levels. This high level of insulin secretion
leads to degranulation of β-cell cytoplasm and is followed by
death of the animals in diabetic ketoacidosis. This phenotype
indicatesthattheinsulinreceptorisnecessaryforpostnatalfuel
homeostasis,butnotforembryonicdevelopmentandmetabolic
control. A similar phenotype is observed in mice lacking both
insulin genes (Ins1 and Ins2) [23].
Interestingly,intraperitonealadministrationofIGF-1causes
a prompt and sustained decrease in plasma glucose levels in
insulin receptor KO mice, indicating that the glucose lowering
effectofIGF-1occursthroughtheIGF-1receptornottheinsulin
receptor[24].Despitethis“potentialcompensation,”theinsulin
receptor KO mice die within 7 days after birth.
TISSUE SPECIFIC KNOCKOUT
MOUSE MODELS
Since global gene knockouts may result in a lethal pheno-
type, conditional knockouts can be created by using tissue spe-
ciﬁc promoters and thereby allow for a detailed analysis of the
gene in a tissue speciﬁc manner. For example, the insulin re-
ceptor gene has been disrupted in various tissues of the mouse
(as described later) by use of the Cre-loxP system [25]. This
system is based on the use of the bacteriophage recombinaseKNOCKOUT MICE, HOMEOSTASIS, AND DIABETES 173
FIGURE 4
Schematic representation of the IR/lox allele before and after recombination and mating strategy to generate tissue-speciﬁc
insulin receptor knockout mice. (Top) The arrows labeled P1, P2, and P3 show the position of the primers used in PCR analyses
to conﬁrm recombination. The knockout allele is shown below the ﬂoxed allele, indicating the deletion of exon 4 in the
event of recombination of the insulin receptor gene [29]. (Lower panel) Strategy for generating tissue-speciﬁc insulin
receptor knockout mice.
Cre to conditionally inactivate genes in mice in which loxP
siteshavebeenintroducedﬂankingsomecriticalelement.LoxP
sites are 34-bp consensus sequences of bacterial DNA, which
allow for directional recombination of two segments of DNA,
eliminating the DNA which occurs in between (Figure 4). In
the case of the insulin receptor, the loxP sites were introduced
around exon 4, since deletion of this exon in the presence of
the Cre recombinase will cause a major deletion and frameshift
mutation with a premature stop of translation at amino acid
308 of the insulin receptor protein. Mice carrying the IRlox al-
lele can then be bred with mice carrying the Cre recombinase
on different promoters to produce a variety of tissue-speciﬁc
knockouts of the insulin receptor. For example, breeding with
an MCK promoter-Cre mouse will produce a muscle-speciﬁc
knockout of the insulin receptor (MIRKO mouse), albumin-
Cre a liver-speciﬁc knockout (LIRKO), aP2-Cre (FIRKO), etc.
(Figure 4).
Muscle-Speciﬁc Insulin Receptor Knockout
(MIRKO) Mice
Since muscle accounts for >80% of post-prandial glucose
uptake in humans and is a site of insulin resistance early in
the pre-diabetic state [26–28], the ﬁrst tissue speciﬁc knockout174 C. R. KAHN
to be created was a muscle-speciﬁc insulin receptor knockout
(MIRKO). As expected, by Western blotting, MIRKO mice
demonstrate almost complete and speciﬁc ablation of insulin
receptor expression in all skeletal muscle, and even a 92% re-
duction in the heart (which had lower Cre expression) [29].
By contrast, insulin receptor expression was unaltered in other
tissues. Mice with a MIRKO were born with the expected fre-
quency and were indistinguishable from their wildtype litter-
mates. Muscle mass was only reduced by ∼10%, and MIRKO
mice showed no difference in spontaneous activity or ability to
run on a treadmill as compared to controls.
The expectation was that an impairment of insulin signaling
in muscle would at least cause systemic glucose intolerance.
Surprisingly,despitethevirtuallackofinsulinsignalinginmus-
cle,theMIRKOmicewereabletomaintaineuglycemiauptoat
least 20 months of age [29]. Moreover, plasma insulin concen-
trations were indistinguishable from normal. Similarly, these
animals were able to clear an intraperitoneal bolus of glucose
withsameefﬁciencyascontrolmice(Figure5A)andresponded
normally to exogenously administered insulin. On euglycemic
clamp studies, the rates of insulin-stimulated whole body glu-
cose uptake were decreased by 45% in MIRKO mice with a
74% decrease in insulin-stimulated muscle glucose transport,
and there was an 87% decrease in insulin-stimulated muscle
glycogen synthesis. Although glucose uptake into muscle was
severely decreased in response to insulin, glucose uptake in
response to exercise was normal [30].
What was also unexpected, however, was that insulin-
stimulated glucose transport in adipose tissue was increased
FIGURE 5
Physiological consequences of muscle-speciﬁc IR gene inactivation. (A) Glucose tolerance tests performed on 4-months old
wildtype, IRlox/lox and MIRKO mice. Results are expressed as mean blood glucose concentration ± SEM. (B) Glucose uptake
into muscle and fat in 4-months old male, IRlox/lox and MIRKO mice [29]. An star ( ) indicates p < 0.05 for the difference
between lox/lox control and MIRKO.
by 3-fold in MIRKO mice (Figure 5B). Thus, the relatively
normal plasma glucose in MIRKO mice may be due to the abil-
ity of exercise to stimulate glucose uptake, as well as a shift of
insulin-stimulated glucose uptake and metabolism to adipose
tissue. As a result of this substrate shift, MIRKO mice devel-
oped a metabolic syndrome with an increased adipose tissue
mass and marked hypertriglyceridemia and a modest increase
in free fatty acids (Figure 6). These ﬁndings (mild obesity,
hypertriglyceridemia and elevated FFA) are hallmarks of the
metabolic syndrome, Syndrome X.
TheMIRKOmicedemonstratetheutilityandvalueoftissue-
speciﬁc knockouts in expanding our insights into the nature of
insulin signaling and testing our concepts of glucose home-
ostasis and the pathogenesis of type 2 diabetes. This mouse
also suggests the presence of some cross-talk between muscle
andfat,whichifitoccursinhumansaswell,couldcontributeto
the increase in obesity in people with genetically programmed
insulin resistance in muscle (Figure 6). Of course, it is possi-
ble that the importance of skeletal muscle as a site for glucose
disposal has been overestimated, or that in addition to a direct
insulin stimulation of glucose uptake into skeletal muscle there
could be indirect effects based on increased blood ﬂow across
skeletal muscle [31] or generation of locally diffusible media-
tors of insulin action from the vasculature, such as nitric oxide
or cGMP [32, 33] that act on muscle to enhance glucose up-
take.Finally,theMIRKOmousealsosuggestsasigniﬁcantrole
of muscle insulin resistance in development of the lipid phe-
notype of the metabolic syndrome, including elevated plasma
triglycerides, FFAs, and central obesity.KNOCKOUT MICE, HOMEOSTASIS, AND DIABETES 175
FIGURE 6
Defects in muscle, fat and liver-speciﬁc insulin receptor knockout mice.
Fat-Specific Insulin Receptor
Knockout (FIRKO) Mice
Although fat tissue accounts for only ∼10% of glucose up-
take[34,35],insulinhasmajoreffectsonadipocytestopromote
adipogenesis, stimulate glucose uptake and lipid synthesis and
inhibit lipolysis [36]. Mice with a speciﬁc knockout of the in-
sulin receptor in both white and brown fat (FIRKO) have been
created using the Cre transgene driven by the adipose-speciﬁc
aP2 promoter [37]. The FIRKO mice were born with the ex-
pectedfrequency,survivedwellafterweaning,andwerefertile.
These mice have a ∼50% decrease in fat pad mass and a ∼30%
decrease in whole body triglyceride content, with normal cir-
culating lipids, free fatty acids and glycerol. Furthermore, the
FIRKO mice are resistant to gaining weight during aging or
following induction of a hypothalamic lesion leading to hyper-
phagia. As a result, these mice not only have normal glucose
tolerance,butfailtodevelopimpairedglucosetolerancedespite
overeating.Thus,itappearsthatinsulinsignalinginadiposetis-
sue is not critical for the maintenance of euglycemia in mice,
but is required for the development and maintenance of normal
triglyceride stores in adipocytes. Other features of the FIRKO
miceareinappropriatelyhighleptinlevelsforfatmassandapo-
larizationofadipocytecellsizewithfatpadsconsistingoflarge
or small fat cells, but very few intermediate sized cells [37].
Interestingly, the FIRKO mice have an increase in mean
lifespan of ∼134 days, as well as a parallel increase in me-
dian and maximum life span (Blueher, Kahn, and Kahn, 2003)
(Figure 6). This extended longevity occurred in two indepen-
dent lines of mice, and in both males and females. Thus, the
FIRKO mouse model support studies in Caenorhabditis ele-
gans and Drosophila showing that insulin-like signaling path-
ways are involved in regulation of longevity and that leanness
and not food restriction is the most beneﬁcial factor on the
extension of lifespan (Figure 6) [38–40].
Brown Adipose-Speciﬁc Insulin Receptor
Knockout (BATIRKO) Mice
Brown adipose tissue is thought to play an important role
in determining peripheral insulin sensitivity [41], as well as
thermaladaptation.Insulinreceptorhasbeeninactivatedinthis
tissue(BATIRKO)usingtheuncouplingprotein-1(UCP1)pro-
moter to drive Cre expression. Although brown adipose tissue
develops normally in these mice, it undergoes atrophy as the
mice age. Surprisingly, the age-dependent loss of brown adi-
pose tissue is associated with an unexpected deterioration of
β-cell function and decrease of β-cell mass, giving rise to hy-
perglycemia [42]. This observation suggests that the mainte-
nance of an adequate β-cell mass some how requires brown
adipose tissue. It remains to be determined whether this is an
endocrine effect of factors produced in brown adipose tissue,
or whether it reﬂects a broader metabolic change.176 C. R. KAHN
Liver-Speciﬁc Insulin Receptor Knockout
(LIRKO) Mice
The liver plays a central role in the control of glucose home-
ostasis and is subject to complex regulation by substrates, in-
sulin and other hormones. The effect of insulin to suppress
hepatic glucose output is the result of inhibition of glycolysis
initially, but with prolonged fasting depends on the ability of
insulintoinhibitgluconeogenesis[43].Insulinresistanceinthe
liver, and especially the loss of the ability of insulin to suppress
hepatic glucose output, are closely correlated with fasting hy-
perglycemia in type 2 diabetes. In addition, the liver plays an
important role in insulin degradation since the clearance of in-
sulininvivooccursprimarilyintheliverandismediatedmainly
by receptor dependent mechanisms.
To deﬁne the role of the liver in glucose homeostasis, mice
were generated with a liver-speciﬁc knockout of the insulin re-
ceptor(LIRKO)bybreedingthemicecarryingtheﬂoxedinsulin
receptorgenewithmicethatexpressCrerecombinaseunderthe
FIGURE 7
LIRKO mice have no insulin signaling in liver and a metabolic phenotype of hepatic insulin resistance. (A) Basal and insulin
stimulated insulin receptor tyrosine phosphorylation, insulin receptor content, IRS-1 tyrosine phosphorylation and p85 binding to
IRS-1 in whole livers from control mice and LIRKO mice. (B) Fed serum insulin levels. (C) Glucose tolerance tests were
performed on 2-month-old male wildtype, IRlox/lox, abl-Cre and LIRKO mice that had been fasted for 16 hours. Animals were
injected with 2 g/kg body weight of glucose. Glucose was measured immediately before injection and 15, 30, 60 and 120 minutes
after injection. Results are expressed as mean blood glucose concentration ± SEM [44].
albumin promoter/enhancer [44, 45]. The insulin receptor ex-
pression and insulin stimulated tyrosine phosphorylation was
unaffected in liver from control mice (WT, IR(lox) and Alb-
Cre), whereas the insulin receptor expression was reduced by
∼95% and insulin receptor autophosphorylation was absent in
liver from LIRKO mice (Figure 7A). Likewise insulin stimu-
lated tyrosine phosphorylation of IRS-1 and binding of IRS-1
to p85 (the regulatory subunit of PI 3-kinase) in livers from the
controlmiceweresimilar,whileIRS-1phosphorylationandp85
bindingwaspracticallyundetectableinLIRKOmice.Although
theLIRKOmiceareofnormalsize,for3–5dayspost-weaning,
LIRKOmicegainlessweightthancontrols,butthisiscorrected
by 6 weeks of age. On gross examination, at all ages, the liv-
ers of LIRKO mice were 50–70% of normal size, and exhibit
some morphological changes with collections of large, oval
cells.
At 2 months of age, male LIRKO mice were hyperglycemic
in the fed sate as compared to controls and exhibited severelyKNOCKOUT MICE, HOMEOSTASIS, AND DIABETES 177
impaired glucose tolerance. Serum insulin levels in LIRKO
males were elevated by 20-fold in both the fed (Figure 7B) and
fasting state. Histological analysis also indicated that LIRKO
mice have a signiﬁcant increase in islet size as they attempt
to compensate for the insulin resistance. Insulin tolerance
tests at 2 months of age demonstrated that LIRKO mice were
completely resistant to the blood glucose lowering effects of
exogenousinsulin.Similarly,glucosetolerancetestsperformed
at 2 months of age demonstrated severe glucose intolerance in
LIRKO mice (Figure 7C). Somewhat surprisingly, by 4 months
of age, the fasting hyperglycemia had disappeared, although
fasting and fed hyperinsulinemia, fed hyperglycemia, insulin
resistance and glucose intolerance remained. In addition,
serum triglycerides and free fatty acids were reduced by
30–50% in 4-month-old male LIRKO mice as compared to
control groups [44].
To gain insight into the role of hepatic insulin signaling
in the action of insulin sensitizing agents, LIRKO mice were
treated with the biguinide metformin and the thiazolidinedione
(TZD) rosiglitazone. Although neither rosiglitazone nor met-
formin altered glucose tolerance or insulin tolerance, LIRKO
mice treated with rosiglitazone did exhibit a reduction in their
low-density lipoprotein (LDL) cholesterol levels.
Taken together, these studies indicate that isolated liver in-
sulin resistance is sufﬁcient to cause severe defects in glu-
cose and lipid homeostasis, but not uncontrolled fasting hy-
perglycemia or diabetes (Figure 6). This defect also leads to
hyperinsulinemia, due to changes in both insulin secretion and
insulin clearance. Furthermore, TZDs may improve some lipid
parameters in the LIRKO mice, whereas metformin requires an
operating insulin signaling system in the liver.
Vascular Endothelial Cell Insulin Receptor
Knockout (VENIRKO) Mice
Insulinreceptorsonvascularendothelialcellshavebeensug-
gested to participate in insulin-regulated glucose homeostasis
by facilitating transcytosis of insulin from the intravascular to
extracellular space, by promoting vasodilation and enhancing
blood ﬂow, and by generation of signaling mediators [46, 47].
To directly address the role of insulin action in endothelial
function, mice with a vascular endothelial cell insulin recep-
tor knockout (VENIRKO) were generated using the Cre-loxP
system (Vicent et al., manuscript submitted). Isolated endothe-
lialcellsofVENIRKOmiceexhibitedcompleterearrangement
of the insulin receptor gene and a >95% decrease in insulin re-
ceptormRNA.Despitepreviousstudiessuggestingaroleofthe
insulin receptor on endothelial cells in control of both glucose
homeostasis and vascular tone, blood glucose and insulin con-
centrations, glucose and insulin tolerance tests, the time course
of insulin action on glucose disposal during a euglycemic-
hyperinsulinemic clamp were comparable in VENIRKO and
control mice. However, both endothelial nitric oxide synthase
(eNOS) and endothelin-1 (ET-1) mRNA levels were reduced
by 30–60% in endothelial cells, aorta, and heart as assessed
by real-time quantitative RT-PCR and Northern blotting, while
expression of vascular endothelial growth factor (VEGF) was
maintainedatnormallevels.VENIRKOalsotendtohavelower
systolic, diastolic and mean blood pressures than controls, but
respond normally to high and low salt diet. On the low salt
diet, however, the VENIRKO mice showed insulin resistance.
Thus, inactivation of the insulin receptor on endothelial cell
has no major consequences on vascular development or glu-
cose homeostasis under basal conditions, but alters expression
of vasoactive mediators and may play a role in maintaining
vascular tone and regulation of insulin sensitivity to dietary salt
intake.
Pancreatic β-Cell-Speciﬁc Insulin Receptor
Knockout (βIRKO) Mice
Whether as a result of autoimmune destruction, as in type 1
diabetes, or as a result of impaired function, as in type 2 dia-
betes,fastinghyperglycemiaisinevitablyassociatedwithsome
degreeofβ-cellfailure.Wedonotknowwhatthecentraldefect
in β-cells of type 2 diabetics is; however, one of the most char-
acteristic features is an impairment of glucose-stimulated in-
sulinsecretion,whichis,atleastinpart,geneticallydetermined
[48].
Under normal circumstances, insulin secretion is regulated
by the products of glucose metabolism in the β-cell [49]. How-
ever, several observations have raised the possibility that sig-
naling through receptor tyrosine kinases also participates in
control of insulin synthesis and release. As described above, a
complete knockout of Irs1 leads to defective insulin secretion
in response to glucose and amino acids [18], while inactivation
of Irs2 leads to impaired β-cell proliferation [14], suggesting a
role of insulin action in control of β-cell function [50].
To directly address the role of insulin signaling in mature
β-cells, mice with the IRlox gene were bred with mice carry-
ing the Cre transgene controlled by the rat insulin 2 promoter
(Rip-Cre transgenic mice) [51]. The Rip-Cre transgenic mice
exhibited speciﬁc Cre expression in insulin-producing β-cells,
but not in non-β-cells or acinar cells [51]. As compared to con-
trol mice, βIRKO mice exhibited an 85% reduction in acute
ﬁrst-phase insulin secretion in response to glucose and virtu-
ally no response in males. In contrast, the acute insulin release
inresponsetoargininewasmaintained.Immunohistochemistry
of the islets showed no differences in islet size or in the ratio
of β to non-β-cells at 2 months of age, and insulin content was178 C. R. KAHN
normal.In4-month-oldcontrolmice,isletsizeandinsulincon-
tent had increased slightly, but this did not occur in the βIRKO
mice.
Upon intraperitoneal glucose challenge, βIRKO mice
showed signiﬁcantly higher glucose levels than in the controls,
and the glucose tolerance continued to worsen with time [51].
Thus, a lack of insulin receptors in β-cells results in a selective
impairment of glucose-dependent insulin release, and leads to
an age-dependent glucose intolerance and, in some mice, overt
diabetes[51].Fromthesedata,itappearsthatsignalingthrough
receptortyrosinekinasesregulatesbothβ-cellproliferationand
insulin secretion.
It is unclear how insulin controls its own secretion and more
work is required to determine the kinetics of insulin regula-
tion of its own secretion. Nevertheless, the idea that insulin
receptor signaling regulates insulin production and exocytosis
is teleologically attractive, in that it would provide a unifying
mechanism for insulin resistance and impaired β-cell function.
Although, the insulin-receptor related receptor (IRR), is also
expressed in β-cells [52], IRR does not appear to be involved
in this process. In fact, metabolic analyses and insulin release
studies from perifused islets of IRR knockouts have failed thus
far to demonstrate a role for this receptor in β-cell function
[53].
Neuron-Speciﬁc Insulin Receptor Knockout
(NIRKO) Mice
Insulin and IGF1 receptors are expressed at high levels in
many brain areas and different cell types, including glial and
neuronal cells [54]. Since neurons metabolize glucose in an
insulin-independent manner, the role of insulin receptor in the
brainhasremainedsomewhatunclear.Todirectlyassesstherole
of insulin in brain, a neuron-speciﬁc insulin receptor knock-
out (NIRKO) was generated using nestin/Cre-mediated abla-
tion [55]. NIRKO mice showed a >95% reduction in the level
of insulin receptor in the brain. The NIRKO mice showed in-
creased food intake and moderate diet-dependent obesity asso-
ciatedwithinsulinresistanceandhypertriglyceridemia.NIRKO
mice also exhibited hypogonadotropic hypogonadism, associ-
ated with impaired maturation of ovarian follicles in females
andreducedspermatogenesisinmales,leadingtoreducedfertil-
ity[55].Thus,insulinreceptorsinbrainplayaroleinthecontrol
of appetite reproduction. Recent studies suggest that this oc-
curs through an effect of insulin on neuropeptide Y (NPY) and
orexin expression (Bruning, personal communication). Other
work has indicated that inhibition of insulin receptors by anti-
sense oligonucleotides and blocking antibodies affects signal-
ing through the melanocortin pathway [56].
DIFFERENT SITES OF INSULIN RESISTANCE
PRODUCE DIFFERENT PHENOTYPES
Muscle Speciﬁc GLUT4 Knockout
(MG4KO) Mice
GLUT4 is referred to as the insulin-sensitive glucose trans-
porter since it is mainly expressed in skeletal muscle, heart
and adipose tissue [27], and mediates glucose transport stimu-
lated by insulin and contraction/exercise [57]. To determine if
differenttypesofinsulinresistanceinasingletissuemightpro-
duce different alterations in glucose homeostasis, the Cre/loxP
sytem was used to selectively disrupt GLUT4 expression in
muscle [58]. To this end, a construct with loxP sites ﬂank-
ing exon 10 (encoding the glucose binding site) of the mouse
GLUT4 gene was introduced into mice using homologous re-
combination, and the resultant mice were bred to the MCK-Cre
mice as described for the MIRKO mouse. The muscle-speciﬁc
GLUT4 knockout (MG4KO) mice had >90–95% reduction of
GLUT4 protein in skeletal muscle and no compensatory in-
crease in GLUT1. Growth curves of the MG4KO mouse were
normal until 6 months of age, after which they tended to gain
weight more slowly [58]. Basal glucose uptake in vitro was
reduced 72% in soleus and 88% in EDL muscles of MG4KO
micecomparedtocontrolsandtheresponsetoinsulinwascom-
pletelyobliterated.FastingglucosewashigherinMG4KOmice
by 8 weeks compared to control, and intraperitoneal glucose
tolerance tests were signiﬁcantly impaired. Intraperitoneal in-
sulin injection and contraction produced no fall in glucose lev-
els in male MG4KO and only a 34% fall in female MG4KO
(p <. 03). Hyperinsulinemic-euglycemic clamp studies of the
mice showed a 55% decrease in insulin-stimulated whole body
glucose uptake in MG4KO mice as compared to wildtype mice
demonstrating a severe insulin resistance in the knockout [59].
The decrease in whole-body glucose uptake could mainly be
attributed to a reduction by 92% in the insulin-stimulated glu-
cose uptake in skeletal muscle of the MG4KO [59]. Thus, in
contrast to the MIRKO mice, the MG4KO mice have severe
whole body insulin resistance, fasting hyperglycemia and glu-
cose intolerance, but show no increase in body fat or associated
hyperlipidemia.
Fat Speciﬁc GLUT4 Knockout Mice
Fat-speciﬁc GLUT4 knockout mice were created by cross-
ing Glut4 loxP mice with mice expressing the Cre recombinase
under the control of the aP2 promoter/enhancer [60]. GLUT4
expression in the resulting mice was markedly reduced in both
brown and white adipose tissue, whereas GLUT1 expression
was normal and the mice showed growth curves similar to con-
trol mice. The basal glucose uptake into adipocytes tended toKNOCKOUT MICE, HOMEOSTASIS, AND DIABETES 179
be reduced by about 40%, and the maximal insulin stimulated
glucose uptake was reduced by 72% in the knockout mice
compared to control mice. In contrast, the basal and insulin
stimulatedglucosetransportintoskeletalmusclewasunaltered.
In vivo studies performed during a hyperinsulinemic-
euglycemic clamp of the GLUT4 fat-speciﬁc knockout mice
showed a 53% decrease in insulin-stimulated whole body
glucose uptake and reductions in glycolysis and glycogen
synthesisby50–67%[60].Insulin-stimulatedglucosetransport
into white and brown adipose tissue was markedly reduced
and surprisingly, the glucose transport into skeletal muscle
was impaired by 40%, despite the preserved expression of
GLUT4 in muscle. This discrepancy between in vivo and
in vitro muscle glucose uptake is suggested to be due to
secondary defects in the in vivo milieu resulting from altered
release of speciﬁc molecules from fat [60]. Furthermore, a
secondary effect of the GLUT4 fat-speciﬁc knockout was also
detected in the liver, in which the ability of insulin to suppress
hepatic glucose production was decreased as compared to
control mice. Thus, the insulin resistance created in fat due
to GLUT4 deﬁciency causes secondarily induced insulin
resistance in other insulin target tissues. The insulin resistance
created by insulin receptor knockout in fat (FIRKO) also
causes a decrease in insulin stimulated glucose uptake into
white adipose tissue [37], however in contrast to the GLUT4
fat-speciﬁc knockout mice, the FIRKO mice are protected
from age-related reduction in whole body glucose and insulin
tolerances. Thus, insulin resistance in fat at the level of the
insulin receptor versus GLUT4 produce dramatically different
metabolic outcomes on both fat and at the whole-body level.
POLYGENIC KNOCKOUT MODELS
Mice with Compound Defects Mimic Human
Type 2 Diabetes
Since type 2 diabetes is polygenic in nature, a heterozygous
doubleknockout mouse model of insulin receptor and IRS-1
has been generated to create a polygenic model of diabetes that
may more closely mimic the human disease. This was possi-
ble since heterozygote insulin receptor and heterozygote IRS-1
knockout mice exhibit only mild subclinical insulin resistance
with a 1.5- to 2-fold elevation in insulin levels and mild
β-cell hyperplasia. In contrast, the IR/IRS-1 doubleheterozy-
gous(DH)knockoutmicemanifestedmarkedinsulinresistance
with 10-fold increases in circulating insulin levels and a 5–30
fold increase in β-cell mass. Despite this islet hyperplasia on
a mixed genetic background, ∼50% of these mice developed
diabetes by 4–6 months of age [61].
Thesecompoundheterozygoteanimalsrevealedseveralfea-
tures of interest. First, despite the genetic nature of the insulin
resistance, like humans, these mice develop diabetes with de-
layed onset. Secondly, the development of diabetes indicates a
marked synergism (epistasis) between the insulin receptor de-
fect (which leads to diabetes in <10% of mice) and the IRS-1
defect (which never leads to diabetes). Finally, on a mixed ge-
netic background only ∼50% of the mice develop diabetes,
even after up to 18 months of follow-up, indicating that an ad-
ditional gene or genes present in the background of these mice
contribute to or protect from the development of diabetes.
Recent experiments have shown that the phenotype of male
mice DH for the insulin receptor and IRS-1 varies markedly
depending on the genetic background. Thus, DH mice on the
C57Bl/6J (B6) background have a high incidence of diabetes
(85% at 6 months of age), whereas the 129Sv strain does not
develop diabetes, despite the genetic defects in insulin signal-
ing (Figure 8). This difference is due to differences in insulin
resistance, rather that β-cell failure.
In order to identify the susceptibility or resistance alleles
we created an F2 intercross between mice on the B6 and 129Sv
backgrounds. The incidence of diabetes in DH male intercross
mice was 60% at 6 months of age and fed blood glucoses
showed a wide variation and a bimodal distribution. Likewise,
the fed plasma insulin levels also exhibited a wide range. The
relationship between fed insulin and glucose levels of the DH
mice described a bell-shaped curve, as has been observed in
several studies of humans with type 2 diabetes [62] and some
rodent models [14]. At any glucose, however, there was a wide
range of insulin values suggesting a wide range of insulin
resistance in the DH mice. Thus, the IR/IRS-1 DH knockout
mouse is similar to human type 2 diabetes with a polygenic
FIGURE 8
Incidence of diabetes with increasing age in wildtype (Wt)
and IR/IRS-1 doubleheterozygous (DH) knockout mice on the
backgrounds of C57Bl/6J (B6) and 129Sv.180 C. R. KAHN
etiology, genetically programmed insulin resistance, a delayed
age of onset and a biphasic relationship between insulin and
glucose levels. A genome-wide scan of the DH intercross mice
has been performed using 90 polymorphic markers with an
average distance of 20 cM. The results suggest that a locus
on chromosome 12 is linked to hyperglycemia and a locus on
chromosome 14 is signiﬁcantly linked to hyperinsulinemia
(Almind et al., manuscript submitted).
Improved Insulin Tolerance in Triple
Heterozygous Knockouts (IR/IRS-1/p85)
Recently, other studies have been extended to produce even
more complex compound heterozygous animals. For example,
mice with three partial defects in insulin signaling (IR/IRS-
1/IRS-2 or IR/IRS-1/p85) have been created [63]. The pheno-
types of these mice illustrate some of the complexity of poly-
genic disease. Thus, the IR/IRS-1/IRS-2 triple heterozygote
mouse has severely impaired glucose tolerance and a doubling
of the incidence of diabetes compared to the double heterozy-
gotes. By contrast, the IR/IRS-1/p85 knockout is less severely
affected than the IR/IRS-1 (±) mouse. In fact, heterozygos-
ity for the p85 allele seems to protect mice from becoming
diabetic [64]. This is demonstrated by the improved intraperi-
toneal insulin tolerance in p85 heterozygous mice as compared
to wildtype mice (Figure 9A), as well as improved insulin tol-
erance in the triple heterozygous knockouts (IR/IRS-1/p85) as
compared to the double heterozygous (IR/IRS-1) knockouts
(Figure 9B). This may be due to an abundance of p85 sub-
unit over p110 (the catalytic subunit) in wildtype mice, and
therebyacompetitionbetweenp85monomerandthep85-p110
dimer causing an ineffective signaling. Thus, a reduction of
p85 results in more efﬁcient signaling and thus p85 may repre-
FIGURE 9
Increased insulin sensitivity in IR/IRS1/p85(±) mice. Insulin
tolerance test were performed on 6-month-old male mice of
the indicated genotypes. Results represent the blood glucose
concentration as a percentage of the starting glucose value and
are expressed as mean ± SEM [66].
sent a novel therapeutic target for enhancing insulin signaling
[65].
SUMMARY AND CONCLUSIONS
The painstaking process of generating constitutive and con-
ditional knockout mice has paid off handsomely. The roles of
the insulin receptor and its intracellular substrates in insulin
action has been established and begun to shed light onto some
of the proteins less obvious functions. We have learned how
genetic predisposition plays itself out in the oligogenic and
heterogeneous pathogenesis of type 2 diabetes and how the
balance of proteins can affect the efﬁciency of signaling both
positivelyandnegatively.TheIRSknockoutmicehavetaughtus
how these proteins provide unique and complementary signals
in insulin action. From the tissue speciﬁc knockouts we have
learned that different tissues contribute uniquely to the patho-
genesis of type 2 diabetes, but not always in the predicted way;
that insulin resistance at different levels in the same tissue may
produce different phenotypes; that tissues possess mechanisms
of communication such that resistance in one tissue affects in-
sulin signaling or metabolism in others; and that insulin has
important effects in tissues not previously considered insulin
responsive, including the brain and β-cells. The result of this
work has led us to develop new hypotheses about the nature of
the insulin action network.
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